{"seq": 1, "variant": "treatment", "cmd": "pm --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm - PubMed CLI tools for AI agents\n\nUsage: pm <command> [OPTIONS]\n\nRecommended workflow:\n  pm collect     Search + fetch + parse in one command (RECOMMENDED)\n  pm filter      Filter JSONL articles by year, journal, author, etc.\n\nAll commands:\n  collect     Search + fetch + parse in one command (RECOMMENDED)\n  search      Search PubMed, return PMIDs\n  fetch       Fetch PubMed XML by PMIDs\n  parse       Parse PubMed XML to JSONL\n  filter      Filter JSONL articles by field patterns\n  cite        Fetch CSL-JSON citations\n  download    Download full-text PDFs\n  diff        Compare two JSONL files by PMID\n  audit       View audit trail and PRISMA report\n  init        Initialize audit trail and cache (.pm/)\n\nExamples:\n  pm collect \"CRISPR cancer\" --max 100 > results.jsonl\n  pm filter --year 2024 --has-abstract < results.jsonl\n\nTip: save results to a file so you can reuse them without re-searching:\n  pm collect \"my query\" > results.jsonl\n  pm filter --year 2024 < results.jsonl\n  pm filter --has-doi < results.jsonl\n\nUse 'pm <command> --help' for command-specific help.\n", "stderr": "", "elapsed_s": 0.276, "ts": 1771594446.6449895}
{"seq": 2, "variant": "treatment", "cmd": "pm collect --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm collect - Collect PubMed articles (search + fetch + parse \u2192 JSONL)\n\nUsage: pm collect [OPTIONS] \"search query\"\n\nOptions:\n  --max N         Maximum results (default: 100)\n  -v, --verbose   Show progress on stderr\n  -h, --help      Show this help message\n\nOutput:\n  JSONL to stdout (one article per line)\n\nExamples:\n  pm collect \"CRISPR cancer therapy\" --max 100 > results.jsonl\n  pm collect --max 50 \"machine learning diagnosis\" > results.jsonl\n\nFor advanced filtering, use the full pipeline:\n  pm search \"query\" | pm fetch | pm parse | pm filter --year 2024\n", "stderr": "", "elapsed_s": 0.275, "ts": 1771594457.6820078}
{"seq": 3, "variant": "treatment", "cmd": "pm filter --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm filter - Filter JSONL articles by field patterns\n\nUsage: pm parse | pm filter [OPTIONS]\n       cat articles.jsonl | pm filter [OPTIONS]\n\nFilter Options:\n  --year PATTERN      Year filter (exact, range, or open-ended)\n                      Examples: 2024, 2020-2024, 2020-, -2024\n  --journal PATTERN   Journal contains PATTERN (case-insensitive)\n  --journal-exact STR Journal equals STR exactly\n  --author PATTERN    Any author contains PATTERN (case-insensitive)\n  --has-abstract      Article has non-empty abstract\n  --has-doi           Article has DOI\n\nGeneral Options:\n  -v, --verbose       Show filter stats on stderr\n  -h, --help          Show this help\n\nExamples:\n  pm filter --year 2020- --journal nature --has-abstract\n  pm filter --author smith\n  pm filter --year 2020-2024\n\nNotes:\n  - Multiple filters combine with AND logic\n  - Malformed JSON lines are silently skipped\n", "stderr": "", "elapsed_s": 0.335, "ts": 1771594464.284362}
{"seq": 4, "variant": "treatment", "cmd": "pm search --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm search - Search PubMed and return PMIDs\n\nUsage: pm search [OPTIONS] \"search query\"\n\nOptions:\n  --max N        Maximum results to return (default: 10000)\n  --refresh      Bypass cache and re-fetch from PubMed\n  -h, --help     Show this help message\n\nOutput:\n  PMIDs to stdout, one per line\n\nTip: for most tasks, use 'pm collect' instead \u2014 it runs search + fetch + parse\nin one command and outputs JSONL directly:\n  pm collect \"CRISPR cancer therapy\" --max 100 > results.jsonl\n\nIf you need raw PMIDs, save them to a file for reuse:\n  pm search \"CRISPR cancer therapy\" --max 100 > pmids.txt\n  cat pmids.txt | pm fetch | pm parse > results.jsonl\n\nQuery syntax:\n  Uses PubMed query syntax. See:\n  https://pubmed.ncbi.nlm.nih.gov/help/#search-tags\n", "stderr": "", "elapsed_s": 0.235, "ts": 1771594469.7231133}
{"seq": 5, "variant": "treatment", "cmd": "pm collect --max 200 -v metabolic tumor volume PSMA PET prostate cancer prognosis", "exit_code": 0, "stdin_lines": 0, "stdout": "{\"pmid\": \"41486328\", \"title\": \"18F-PSMA-1007 PET/CT tumor volume quantification: a game-changing prognostic biomarker for first-line ARPI therapy in metastatic castration-resistant prostate cancer.\", \"authors\": [\"Yang Liping\", \"She Tianyu\", \"Jiang Zhiyun\", \"Xu Shichuan\", \"Wang Yuan\", \"Liu Shijia\", \"Wang Kezheng\", \"Li Ping\", \"Duan Xiaoyi\"], \"journal\": \"Japanese journal of radiology\", \"year\": \"2026\", \"date\": \"2026-02\", \"abstract\": \"This study evaluates the prognostic value of baseline 18F-PSMA-1007 PET/CT-derived volumetric metabolic parameters in metastatic castration-resistant prostate cancer (mCRPC) patients initiating first-line androgen receptor pathway inhibitor (ARPI) therapy, while exploring their relationship with serum PSA and developing a risk stratification model. Both wbPSMA-TV (r\u2009=\u20090.70) and wbTL-PSMA (r\u2009=\u20090.67) correlated with baseline PSA. Multivariable analysis identified bone metastasis count (adjusted OR [aOR] 0.19, 95% CI 0.11-0.35; P\u2009<\u20090.001) and wbPSMA-TV (aOR\u2009=\u20090.77, 95% CI 0.65-0.91; P\u2009<\u20090.001) as independent predictors of early PSA response. Baseline wbTL-PSMA\u2009\u2265\u2009231.4 SUV cm3 independently predicted shorter OS (10.3 vs. 22.2 months, P\u2009<\u20090.001). Multivariable Cox regression confirmed wbTL-PSMA (adjusted hazard ratio [aHR] 3.160, 95% CI 2.490-4.016; P\u2009<\u20090.001), wbPSMA-TV (aHR 3.010, 95% CI 2.467-3.683; P\u2009<\u20090.001), number of bone metastases (aHR 2.510, 95% CI 1.893-3.148; P\u2009<\u20090.001), and PSA level (aHR 2.995, 95% CI 2.810-3.190; P\u2009<\u20090.001) as OS determinants. The RF model stratified patients into low- (median OS not reached), intermediate-(11.8 months), and high-risk (9.55 months) groups (P\u2009<\u20090.001). Baseline 18F-PSMA-1007 PET/CT-derived volumetric parameters (wbPSMA-TV and wbTL-PSMA) serve as independent prognostic biomarkers for survival in mCRPC patients receiving ARPI therapy. Integration of these metrics with clinical variables enhances risk stratification, potentially guiding personalized therapeutic strategies. Prospective validation is warranted to confirm clinical utility.\", \"abstract", "stderr": "Searching PubMed: \"metabolic tumor volume PSMA PET prostate cancer prognosis\" (max 200)...\nFetching batch 1 (68 PMIDs)...\n", "elapsed_s": 2.924, "ts": 1771594489.3376923}
{"seq": 6, "variant": "treatment", "cmd": "pm collect --max 200 -v (MTV OR \"metabolic tumor volume\" OR \"total tumor volume\") AND (PSMA OR \"prostate-specific membrane antigen\") AND (PET OR PET/CT) AND (prostate cancer OR prostatic neoplasm) AND (prognostic OR prognosis OR survival OR outcome)", "exit_code": 0, "stdin_lines": 0, "stdout": "{\"pmid\": \"41703276\", \"title\": \"Distinct prognostic value of [18F]FDG PET and [68Ga]Ga-PSMA-11 PET in advanced hormone-sensitive prostate cancer.\", \"authors\": [\"Li Ang\", \"Wu Haotian\", \"Zhou Xiang\", \"Zhu Yinjie\", \"Zhang Weiwei\", \"Shen Kai\", \"Tang Linglin\", \"Yi Jiayan\", \"Liu Bo\", \"Su Ruopeng\", \"Liu Xinyu\", \"Chai Xinyu\", \"Wang Qi\", \"Pan Jiahua\", \"Xue Wei\"], \"journal\": \"Communications medicine\", \"year\": \"2026\", \"date\": \"2026-02-17\", \"abstract\": \"This study aimed to evaluate the distinct prognostic value of [18F]FDG and [68Ga]Ga-PSMA-11 PET imaging in advanced hormone-sensitive prostate cancer, highlighting their complementary roles at both patient and lesion levels. This study retrospectively included 298 patients with newly diagnosed prostate cancer who underwent baseline dual-tracer PET imaging. Quantitative PET parameters for both [18F]FDG and [68Ga]Ga-PSMA-11 were extracted. Clinical outcomes, including progression-free survival, biochemical response, and radiographic response, were collected during follow-up. Lesion-based analysis was performed in 267 measurable lesions to evaluate the association between tracer uptake and local radiographic response, as determined by changes in lesion diameter following systemic therapy. Here we show that higher whole-body [18F]FDG uptake, including total lesion glycolysis (HR\u2009=\u20093.525, p\u2009<\u20090.001) and metabolic tumor volume (HR\u2009=\u20092.757, p\u2009<\u20090.001), is significantly associated with shorter progression-free survival. In contrast, only PSMA-derived tumor volume (HR\u2009=\u20092.019, p\u2009=\u20090.018), but not total lesion PSMA uptake (HR\u2009=\u20091.438, p\u2009=\u20090.221), demonstrates prognostic value. Moreover, patients with higher whole-body [18F]FDG burden receive greater benefit from chemotherapy (HR\u2009=\u20092.936, p\u2009=\u20090.004). At the lesion level, higher [68Ga]Ga-PSMA-11 uptake is significantly correlated with more favorable radiographic response (p\u2009<\u20090.001), while lesion-level [18F]FDG uptake does not demonstrate predictive value. [18F]FDG PET and [68Ga]Ga-PSMA-11 PET provide distinct but complementary prognostic", "stderr": "Searching PubMed: \"(MTV OR \"metabolic tumor volume\" OR \"total tumor volume\") AND (PSMA OR \"prostate-specific membrane antigen\") AND (PET OR PET/CT) AND (prostate cancer OR prostatic neoplasm) AND (prognostic OR prognosis OR survival OR outcome)\" (max 200)...\nFetching batch 1 (62 PMIDs)...\n", "elapsed_s": 2.056, "ts": 1771594507.041271}
{"seq": 7, "variant": "treatment", "cmd": "pm collect --max 200 -v PSMA PET tumor volume prostate", "exit_code": 0, "stdin_lines": 0, "stdout": "{\"pmid\": \"41703276\", \"title\": \"Distinct prognostic value of [18F]FDG PET and [68Ga]Ga-PSMA-11 PET in advanced hormone-sensitive prostate cancer.\", \"authors\": [\"Li Ang\", \"Wu Haotian\", \"Zhou Xiang\", \"Zhu Yinjie\", \"Zhang Weiwei\", \"Shen Kai\", \"Tang Linglin\", \"Yi Jiayan\", \"Liu Bo\", \"Su Ruopeng\", \"Liu Xinyu\", \"Chai Xinyu\", \"Wang Qi\", \"Pan Jiahua\", \"Xue Wei\"], \"journal\": \"Communications medicine\", \"year\": \"2026\", \"date\": \"2026-02-17\", \"abstract\": \"This study aimed to evaluate the distinct prognostic value of [18F]FDG and [68Ga]Ga-PSMA-11 PET imaging in advanced hormone-sensitive prostate cancer, highlighting their complementary roles at both patient and lesion levels. This study retrospectively included 298 patients with newly diagnosed prostate cancer who underwent baseline dual-tracer PET imaging. Quantitative PET parameters for both [18F]FDG and [68Ga]Ga-PSMA-11 were extracted. Clinical outcomes, including progression-free survival, biochemical response, and radiographic response, were collected during follow-up. Lesion-based analysis was performed in 267 measurable lesions to evaluate the association between tracer uptake and local radiographic response, as determined by changes in lesion diameter following systemic therapy. Here we show that higher whole-body [18F]FDG uptake, including total lesion glycolysis (HR\u2009=\u20093.525, p\u2009<\u20090.001) and metabolic tumor volume (HR\u2009=\u20092.757, p\u2009<\u20090.001), is significantly associated with shorter progression-free survival. In contrast, only PSMA-derived tumor volume (HR\u2009=\u20092.019, p\u2009=\u20090.018), but not total lesion PSMA uptake (HR\u2009=\u20091.438, p\u2009=\u20090.221), demonstrates prognostic value. Moreover, patients with higher whole-body [18F]FDG burden receive greater benefit from chemotherapy (HR\u2009=\u20092.936, p\u2009=\u20090.004). At the lesion level, higher [68Ga]Ga-PSMA-11 uptake is significantly correlated with more favorable radiographic response (p\u2009<\u20090.001), while lesion-level [18F]FDG uptake does not demonstrate predictive value. [18F]FDG PET and [68Ga]Ga-PSMA-11 PET provide distinct but complementary prognostic", "stderr": "Searching PubMed: \"PSMA PET tumor volume prostate\" (max 200)...\nFetching batch 1 (200 PMIDs)...\n", "elapsed_s": 3.084, "ts": 1771594525.017555}
{"seq": 8, "variant": "treatment", "cmd": "pm collect --max 200 -v \"total lesion\" PSMA prostate cancer prognostic", "exit_code": 0, "stdin_lines": 0, "stdout": "{\"pmid\": \"41703276\", \"title\": \"Distinct prognostic value of [18F]FDG PET and [68Ga]Ga-PSMA-11 PET in advanced hormone-sensitive prostate cancer.\", \"authors\": [\"Li Ang\", \"Wu Haotian\", \"Zhou Xiang\", \"Zhu Yinjie\", \"Zhang Weiwei\", \"Shen Kai\", \"Tang Linglin\", \"Yi Jiayan\", \"Liu Bo\", \"Su Ruopeng\", \"Liu Xinyu\", \"Chai Xinyu\", \"Wang Qi\", \"Pan Jiahua\", \"Xue Wei\"], \"journal\": \"Communications medicine\", \"year\": \"2026\", \"date\": \"2026-02-17\", \"abstract\": \"This study aimed to evaluate the distinct prognostic value of [18F]FDG and [68Ga]Ga-PSMA-11 PET imaging in advanced hormone-sensitive prostate cancer, highlighting their complementary roles at both patient and lesion levels. This study retrospectively included 298 patients with newly diagnosed prostate cancer who underwent baseline dual-tracer PET imaging. Quantitative PET parameters for both [18F]FDG and [68Ga]Ga-PSMA-11 were extracted. Clinical outcomes, including progression-free survival, biochemical response, and radiographic response, were collected during follow-up. Lesion-based analysis was performed in 267 measurable lesions to evaluate the association between tracer uptake and local radiographic response, as determined by changes in lesion diameter following systemic therapy. Here we show that higher whole-body [18F]FDG uptake, including total lesion glycolysis (HR\u2009=\u20093.525, p\u2009<\u20090.001) and metabolic tumor volume (HR\u2009=\u20092.757, p\u2009<\u20090.001), is significantly associated with shorter progression-free survival. In contrast, only PSMA-derived tumor volume (HR\u2009=\u20092.019, p\u2009=\u20090.018), but not total lesion PSMA uptake (HR\u2009=\u20091.438, p\u2009=\u20090.221), demonstrates prognostic value. Moreover, patients with higher whole-body [18F]FDG burden receive greater benefit from chemotherapy (HR\u2009=\u20092.936, p\u2009=\u20090.004). At the lesion level, higher [68Ga]Ga-PSMA-11 uptake is significantly correlated with more favorable radiographic response (p\u2009<\u20090.001), while lesion-level [18F]FDG uptake does not demonstrate predictive value. [18F]FDG PET and [68Ga]Ga-PSMA-11 PET provide distinct but complementary prognostic", "stderr": "Searching PubMed: \"\"total lesion\" PSMA prostate cancer prognostic\" (max 200)...\nFetching batch 1 (35 PMIDs)...\n", "elapsed_s": 1.293, "ts": 1771594541.9745083}
{"seq": 9, "variant": "treatment", "cmd": "pm filter --year 2020- --has-abstract -v", "exit_code": 0, "stdin_lines": 253, "stdout": "{\"pmid\": \"41486328\", \"title\": \"18F-PSMA-1007 PET/CT tumor volume quantification: a game-changing prognostic biomarker for first-line ARPI therapy in metastatic castration-resistant prostate cancer.\", \"authors\": [\"Yang Liping\", \"She Tianyu\", \"Jiang Zhiyun\", \"Xu Shichuan\", \"Wang Yuan\", \"Liu Shijia\", \"Wang Kezheng\", \"Li Ping\", \"Duan Xiaoyi\"], \"journal\": \"Japanese journal of radiology\", \"year\": \"2026\", \"date\": \"2026-02\", \"abstract\": \"This study evaluates the prognostic value of baseline 18F-PSMA-1007 PET/CT-derived volumetric metabolic parameters in metastatic castration-resistant prostate cancer (mCRPC) patients initiating first-line androgen receptor pathway inhibitor (ARPI) therapy, while exploring their relationship with serum PSA and developing a risk stratification model. Both wbPSMA-TV (r\u2009=\u20090.70) and wbTL-PSMA (r\u2009=\u20090.67) correlated with baseline PSA. Multivariable analysis identified bone metastasis count (adjusted OR [aOR] 0.19, 95% CI 0.11-0.35; P\u2009<\u20090.001) and wbPSMA-TV (aOR\u2009=\u20090.77, 95% CI 0.65-0.91; P\u2009<\u20090.001) as independent predictors of early PSA response. Baseline wbTL-PSMA\u2009\u2265\u2009231.4 SUV cm3 independently predicted shorter OS (10.3 vs. 22.2 months, P\u2009<\u20090.001). Multivariable Cox regression confirmed wbTL-PSMA (adjusted hazard ratio [aHR] 3.160, 95% CI 2.490-4.016; P\u2009<\u20090.001), wbPSMA-TV (aHR 3.010, 95% CI 2.467-3.683; P\u2009<\u20090.001), number of bone metastases (aHR 2.510, 95% CI 1.893-3.148; P\u2009<\u20090.001), and PSA level (aHR 2.995, 95% CI 2.810-3.190; P\u2009<\u20090.001) as OS determinants. The RF model stratified patients into low- (median OS not reached), intermediate-(11.8 months), and high-risk (9.55 months) groups (P\u2009<\u20090.001). Baseline 18F-PSMA-1007 PET/CT-derived volumetric parameters (wbPSMA-TV and wbTL-PSMA) serve as independent prognostic biomarkers for survival in mCRPC patients receiving ARPI therapy. Integration of these metrics with clinical variables enhances risk stratification, potentially guiding personalized therapeutic strategies. Prospective validation is warranted to confirm clinical utility.\", \"abstract", "stderr": "242 articles passed filters\n", "elapsed_s": 0.247, "ts": 1771594580.3828409}
{"seq": 10, "variant": "treatment", "cmd": "pm filter --year 2020- --has-abstract", "exit_code": 0, "stdin_lines": 253, "stdout": "{\"pmid\": \"41486328\", \"title\": \"18F-PSMA-1007 PET/CT tumor volume quantification: a game-changing prognostic biomarker for first-line ARPI therapy in metastatic castration-resistant prostate cancer.\", \"authors\": [\"Yang Liping\", \"She Tianyu\", \"Jiang Zhiyun\", \"Xu Shichuan\", \"Wang Yuan\", \"Liu Shijia\", \"Wang Kezheng\", \"Li Ping\", \"Duan Xiaoyi\"], \"journal\": \"Japanese journal of radiology\", \"year\": \"2026\", \"date\": \"2026-02\", \"abstract\": \"This study evaluates the prognostic value of baseline 18F-PSMA-1007 PET/CT-derived volumetric metabolic parameters in metastatic castration-resistant prostate cancer (mCRPC) patients initiating first-line androgen receptor pathway inhibitor (ARPI) therapy, while exploring their relationship with serum PSA and developing a risk stratification model. Both wbPSMA-TV (r\u2009=\u20090.70) and wbTL-PSMA (r\u2009=\u20090.67) correlated with baseline PSA. Multivariable analysis identified bone metastasis count (adjusted OR [aOR] 0.19, 95% CI 0.11-0.35; P\u2009<\u20090.001) and wbPSMA-TV (aOR\u2009=\u20090.77, 95% CI 0.65-0.91; P\u2009<\u20090.001) as independent predictors of early PSA response. Baseline wbTL-PSMA\u2009\u2265\u2009231.4 SUV cm3 independently predicted shorter OS (10.3 vs. 22.2 months, P\u2009<\u20090.001). Multivariable Cox regression confirmed wbTL-PSMA (adjusted hazard ratio [aHR] 3.160, 95% CI 2.490-4.016; P\u2009<\u20090.001), wbPSMA-TV (aHR 3.010, 95% CI 2.467-3.683; P\u2009<\u20090.001), number of bone metastases (aHR 2.510, 95% CI 1.893-3.148; P\u2009<\u20090.001), and PSA level (aHR 2.995, 95% CI 2.810-3.190; P\u2009<\u20090.001) as OS determinants. The RF model stratified patients into low- (median OS not reached), intermediate-(11.8 months), and high-risk (9.55 months) groups (P\u2009<\u20090.001). Baseline 18F-PSMA-1007 PET/CT-derived volumetric parameters (wbPSMA-TV and wbTL-PSMA) serve as independent prognostic biomarkers for survival in mCRPC patients receiving ARPI therapy. Integration of these metrics with clinical variables enhances risk stratification, potentially guiding personalized therapeutic strategies. Prospective validation is warranted to confirm clinical utility.\", \"abstract", "stderr": "", "elapsed_s": 0.235, "ts": 1771594638.4777446}
